Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Gritstone Bio Inc chart...

About the Company

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

$143M

Total Revenue

191

Employees

$232M

Market Capitalization

-1.93

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GRTS News

Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?

13h ago, source: Zacks.com on MSN

Investors in Gritstone bio, Inc. GRTS need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 19, 2024 $2.00 Put had some of the highest implied ...

Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates

10d ago, source:

Gritstone bio, Inc. (NASDAQ:GRTS) just released its latest yearly results and things are looking bullish. Overall results ...

Why Is Gritstone Bio Stock Trading Lower?

6d ago, source: Hosted on MSN

Gritstone bio Inc (NASDAQ:GRTS) shares are trading lower after the company announced an approximately 40% reduction of its ...

Domino effect around next-generation Covid vaccine trial pushes Gritstone to cut 40% of staff

17d ago, source: The Business Journals

Gritstone Bio Inc. will cut 94 jobs — or 40% of its workforce — after the delay of a Covid-19 vaccine clinical trial led to a domino effect stopping a payout the Emeryville company had hoped ...

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

13d ago, source: Business Insider

March 05, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for ...

Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

13d ago, source: Nasdaq

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago. These ...

Gritstone bio Announces Workforce Reduction

18d ago, source: Stockhouse

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS

5d ago, source: Business Insider

New York, New York--(Newsfile Corp. - March 13, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS). Such ...

Gritstone Oncology Inc (GRTS)

14d ago, source: Investing

EMERYVILLE, Calif. - Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company, has announced a significant workforce reduction of approximately 40%. This decision ...

Gritstone Bio Inc GRTS

26d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gritstone bio Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...